

Appl. No. 10/027,603
Amendment dated June 1, 2004
Reply to Office Action of January 30, 2004

Amendments to the Specification

Please replace the paragraph beginning at page 7, line 26 with the following amended paragraph:

The invention further concerns anti-EG-VEGF antibodies, in particular anti-EG-VEGF monoclonal antibodies ~~1C6-1H6-1D7~~ 1C6, ~~2A3-1C5-1F3~~ 2A3, ~~2A8-1H4-1E7~~ 2A8, and ~~4H9-1A7-1H6~~ 4H9, and antibodies that bind essentially the same epitope(s) as any of these antibodies. Fragments of such antibodies, as well as chimeric, humanized, or human antibodies sharing an epitope with any of monoclonal antibodies ~~1C6-1H6-1D7~~ 1C6, ~~2A3-1C5-1F3~~ 2A3, ~~2A8-1H4-1E7~~ 2A8, and ~~4H9-1A7-1H6~~ 4H9 are specifically included herein, as are antibody variants comprising amino acid alterations (substitutions, insertions and/or deletions) within the sequence, including the variable region, of such antibodies, as long as the antibodies retain the qualitative antigen-binding properties of any of monoclonal antibodies ~~1C6-1H6-1D7~~ 1C6, ~~2A3-1C5-1F3~~ 2A3, ~~2A8-1H4-1E7~~ 2A8, and ~~4H9-1A7-1H6~~ 4H9.

Please replace the paragraph beginning at page 9, line 23 with the following amended paragraph:

Figures 10A-~~CB~~ are a displacement plot and scatchard plot, respectively, showing ¹²⁵I-EG-VEGF-his ligand binding analysis in bovine adrenal cortical capillary endothelial cells (ACE).

Please replace the paragraph beginning at page 12, line 19 with the following amended paragraph:

Figures 20A-~~PQ~~ provide the complete source code for the ALIGN-2 sequence comparison computer code. This source code may be routinely compiled for use on a UNIX operation system to provide the ALIGN-2 sequence comparison computer program.

Please replace the paragraph beginning at page 74, line 4 with the following amended paragraph:

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')₂ bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be

Appl. No. 10/027,603
Amendment dated June 1, 2004
Reply to Office Action of January 30, 2004

prepared can be prepared using chemical linkage. Brennan *et al.*, Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')₂ fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Please replace the paragraph beginning at page 118, line 8 with the following amended paragraph:

The following materials have been deposited with the American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209, USA (ATCC):

Material	ATCC Dep. No.	Deposit Date
DNA60621-1516	203091	August 4, 1998
1C6	<u>PTA-4119</u>	<u>March 5, 2002</u>
2A3	<u>PTA-4120</u>	<u>March 5, 2002</u>
2A8	<u>PTA-4121</u>	<u>March 5, 2002</u>
4H9	<u>PTA-4122</u>	<u>March 5, 2002</u>